Stock EVGN EVOGENE LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Evogene Ltd.

Equities

EVGN

IL0011050551

Delayed TEL AVIV STOCK EXCHANGE
Other stock markets
 04:50:30 2024-04-24 am EDT 		5-day change 1st Jan Change
247 ILa +5.20% Intraday chart for Evogene Ltd. -4.89% -17.61%
Apr. 02 Evogene Ltd. and The Kitchen FoodTech Hub Establishes Finally Foods Ltd CI
Mar. 20 Evogene Receives Minimum Bid Price Non-Compliance Notice From Nasdaq MT

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
EVOGENE LTD. Stock Evogene Ltd.
-17.61% 31.44M - -
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+3.13% 43.43B
B
LONZA GROUP AG Stock Lonza Group AG
+47.24% 41.69B
A
MODERNA, INC. Stock Moderna, Inc.
+8.49% 41.31B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-10.82% 27.14B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.26% 25.28B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.69% 18.47B
B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+1.58% 12.33B
C+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.83% 12.59B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.63% 11.03B
B+
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-

Consensus

Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. EVGN Stock
  4. Ratings Evogene Ltd.